Biology Reference
In-Depth Information
Barcus, M.J., Basri, H., Picarima, H., Manyakori, C., Sekartuti, et al., 2007. Demographic risk
factors for severe and fatal vivax and falciparum malaria among hospital admissions in
northeastern Indonesian Papua. Am. J. Trop. Med. Hyg. 77, 984-991.
Barnadas, C., Ratsimbasoa, A., Tichit, M., Bouchier, C., Jahevitra, M., et al., 2008.
Plasmodium
vivax
resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in
pvmdr1 and pvcrt-o genes. Antimicrob. Agents Chemother. 52, 4233-4240.
Berliner, R.W., Earle, D.P., Taggart, J.V., Zubrod, C.G., Welch, W.J., et al., 1948a. Studies
on the chemotherapy of the human malarias. VI. The physiological disposition, anti-
malarial activity, and toxicity of several derivatives of 4-aminoquinoline. J. Clin. Invest.
27, 98-107.
Berliner, R.W., Earle, D.P.J., Taggart, J.V., Atchley, A., Shannon, J.A., 1948b. Studies on the
chemotherapy of the human malarias.VII. The antimalarial activity of pamaquine. J. Clin.
Invest. 27, 108-113.
Beutler, E., 2008. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective.
Blood 111, 16-24.
Brosius, O.T., 1927. Plasmochin in malaria. Section II p. 26-81. In: Medical Department,
Sixteenth Annual Report United Fruit Company, Boston.
Carlini, M.E., White Jr., A.C., Atmar, R.L., 1999.Vivax malaria complicated by adult respira-
tory distress syndrome. Clin. Infect. Dis. 28, 1182-1183.
Carmona-Fonseca, J., Maestre, A., 2009. Prevention of
Plasmodium vivax
malaria recurrence:
efficacy of the standard total dose of primaquine administered over 3 days. Acta Trop.
112, 188-192.
Cedillos, R.A., Warren, M., Jeffery, G.M., 1978. Field evaluation of primaquine in the control
of
Plasmodium vivax
. Am. J. Trop. Med. Hyg. 27, 466-472.
Chandramohan, D., Jaffar, S., Greenwood, B., 2002. Use of clinical algorithms for diagnosing
malaria. Trop. Med. Int. Health 7, 45-52.
Chattopadhyay, R., Velmurugan, S., Chakiath, C., Andrews Donkor, L., Milhous, W., et al.,
2010. Establishment of an in vitro assay for assessing the effects of drugs on the liver
stages of
Plasmodium vivax
malaria. PLoS ONE 5, e14275.
Chen, N., Auliff, A., Rieckmann, K., Gatton, M., Cheng, Q., 2007. Relapses of
Plasmodium
vivax
infection result from clonal hypnozoites activated at predetermined intervals.
J. Infect. Dis. 195, 934-941.
Chen, J.H., Lu, F., Lim, C.S., Kim, J.Y., Ahn, H.J., et al., 2010. Detection of
Plasmodium vivax
infection in the Republic of Korea by loop-mediated isothermal amplification (LAMP).
Acta Trop. 113, 61-65.
Chotivanich, K., Udomsangpetch, R., Chierakul, W., Newton, P.N., Ruangveerayuth, R.,
et al., 2004. In vitro efficacy of antimalarial drugs against
Plasmodium vivax
on the west-
ern border of Thailand. Am. J. Trop. Med. Hyg. 70, 395-397.
Chotivanich, K., Sattabongkot, J., Choi, Y.K., Park, J.S., Sritabal, J., et al., 2009. Antimalarial
drug susceptibility of
Plasmodium vivax
in the Republic of Korea. Am. J. Trop. Med. Hyg.
80, 902-904.
Clark, W.M., 1946. History of the co-operative wartime program. A Survey of Antimalarial
Drugs 1941-1945, vol. IJW Edwards, Ann Harbor, Michigan, pp. 2-57.
Clayman, C.B., Arnold, J., Hockwald, R.S.,Yount, E.H.J., Edgcomb, J.H., et al., 1952. Toxicity
of primaquine in Caucasians. J. Am. Med. Assoc. 149, 1563-1568.
Clyde, D.F., McCarthy,V.C., 1977. Radical cure of Chesson strain vivax malaria in man by 7,
not 14, days of treatment with primaquine. Am. J. Trop. Med. Hyg. 26, 562-563.
Clyde, D.F., 1981. Clinical problems associated with the use of primaquine as a tissue schizon-
tocidal and gametocytocidal drug. Bull. World Health Organ. 59, 391-395.
Coatney, G.R., Cooper, W.C., Ruhe, D.S., 1948. Studies in human malaria. VI. The organi-
zation of a program for testing potential antimalarial drugs in prisoner volunteers.
Am. J. Epidemiol. 47, 112-119.
